- Home
- KLTOW vs FLG^A Comparison
KLTOW vs FLG^A Comparison
Compare KLTOW & FLG^A Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$0.10
Company Overview
Basic Information| Metric | KLTOW | FLG^A |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 3 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | KLTOW | FLG^A |
|---|---|---|
| Price | $0.10 | N/A |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | N/A | N/A |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | N/A |
| 52 Week High | N/A | N/A |
Technical Indicators
Market Signals| Indicator | KLTOW | FLG^A |
|---|---|---|
| Relative Strength Index (RSI) | 42.84 | N/A |
| Support Level | $0.10 | N/A |
| Resistance Level | $0.11 | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 14.05 | 0.00 |
Price Performance
Historical Comparison KLTOW
FLG^A
About KLTOW Klotho Neurosciences Inc. Warrant
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.